Leflunomide Stada

Leflunomide, the active ingredient in Leflunomide Stada, is an immunomodulatory agent presented as a tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients, acting as a disease‑modifying antirheumatic drug to slow joint damage and reduce inflammation.

GNH USA supplies Leflunomide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug used in autoimmune joint disorders.

- Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage. - Psoriatic arthritis: improves joint symptoms and may lessen associated skin lesions. - Active rheumatoid arthritis: helps achieve disease control when conventional therapy is insufficient.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: loose stools that may be intermittent. - Nausea: feeling of sickness often accompanying meals. - Alopecia: temporary thinning or loss of hair. - Rash: mild skin irritation or redness.

Serious or Rare Side Effects: - Liver toxicity: elevated enzymes or hepatitis requiring monitoring. - Severe infections: increased susceptibility to bacterial or viral infections. - Pulmonary toxicity: interstitial lung disease presenting with cough or breathlessness. - Teratogenicity: risk of fetal malformations if exposure occurs during pregnancy.

Before initiating therapy, several safety considerations are recommended.

- Monitor liver function: obtain baseline tests and repeat periodically. - Check blood pressure: monitor regularly as hypertension may develop. - Assess for infection: avoid starting therapy in the presence of active infection. - Contraindicated in pregnancy: do not use in pregnant women; effective contraception required. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: may increase INR and bleeding risk. - Methotrexate: combined use can heighten hepatotoxicity. - Cholesterol‑binding resins (e.g., cholestyramine): reduce leflunomide exposure.

Moderate Interactions (Monitor Closely): - Azathioprine: enhanced immunosuppression, monitor blood counts. - Cyclosporine: possible increase in leflunomide levels. - Statins: may raise risk of muscle toxicity; observe for myopathy.